Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
Schizophrenia
About this trial
This is an interventional treatment trial for Schizophrenia focused on measuring Schizoaffective Disorder, Depressed Type, Schizophreniform Disorder, First-Episode Schizophrenia, Supported Employment, Cognitive Remediation, Health Behavior Training, Antipsychotic Medication
Eligibility Criteria
Inclusion Criteria: Diagnosis of schizophrenia, schizoaffective disorder (depressed type), or schizophreniform disorder First major episode of psychotic symptoms occurred within 2 years prior to study entry Exclusion Criteria: Neurological disorder or injury (e.g., encephalitis, epilepsy, traumatic brain injury) Mental retardation (e.g., premorbid intelligence quotient (IQ) less than 70) Significant alcohol or substance use during last 6 months Unable to complete research measures in English Any condition that may make risperidone use medically inadvisable
Sites / Locations
- Semel Institute for Neuroscience and Human Behavior at UCLA
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
Cog Remediation, risperidone injection
Healthy Behavior Training, risperidone injection
Cog Remediation, oral risperidone
Healthy Behavior Training, oral risperidone
Participants will receive cognitive remediation training plus risperidone, administered via injection.
Participants will receive health behavior training plus risperidone, administered via injection.
Participants will receive cognitive remediation training plus risperidone administered orally.
Participants will receive health behavior training plus risperidone administered orally.